in the current issue of the Journal of Human Hypertension supports these findings.
The angiotensin-converting enzyme (ACE) inhibitors received better credit than the calcium antagonists, perhaps because ACE inhibitors reduce morbidity and mortality in patients with congestive heart failure and they protect the kidneys in diabetic and non-diabetic nephropathy. [17] [18] [19] [20] Moreover, recently it has been shown that ACE inhibitors may reduce cardiovascular morbidity and mortality in high-risk patients. 21 ACE inhibitors have not been accused of causing cancer. Indeed, few studies showed that the use of ACE inhibitors may be associated with cancer. In the prospective study of left ventricular dysfunction (SOLVD) of patients with congestive heart failure, followed for 41.4 months, those who received enalapril had a slightly higher incidence of malignancy than those who received placebo (odds ratio of 1.59; 95% CI, 0.90 to 2.82). 17 In another prospective randomised trial of 583 patients with renal insufficiency, followed for 3 years, those who received benazepril exhibited a slightly higher incidence of malignancy than did those who received placebo (odds ratio of 1.52, 95% CI, 0.45 to 5.42). 20 However, in a retrospective cohort study, recently it has been shown that ACE inhibitors may protect against malignancies. 22 In this regard, the study by Stahl et al 16 allows us to rule out the association between the use of ACE inhibitors and cancer, but it also cannot support the observation that ACE inhibitors confer protection against cancer.
Stahl et al 16 chose diuretics as a reference drug. However, diuretics are the only drug class that is clearly associated with increased risk of renal cell carcinoma. 23 Should the authors compare the calcium antagonists and ACE inhibitors with no treatment, the results could be slightly different.
The fact that both drugs are not associated with total cancer mortality does not rule out the possibility that they may be related to site-specific cancer, as is the case with diuretics. 23 Ongoing long-term prospective studies will tell us more about the carcinogenicity of calcium antagonists and ACE inhibitors.
